Evolus Inc. Common Stock (EOLS)
Stock · NASDAQ · Health Care
$7.1as of 10/16/2026
Price chart
Active signals
EOLS Signal Track Record
How signals performed across all stocks →What EOLS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -0.2% | 50% | October 2, 2026 |
| Bollinger Band BreakdownActive now | 20 | -3.3% | 45% | October 2, 2026 |
| Bollinger Band Breakout | 20 | +10.4% | 65% | August 6, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -11.9% | 33% | July 22, 2026 |
| Any 20-session window (baseline) | -1.5% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EOLS
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes vario…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 353
- Website
- www.evolus.com/
Fundamentals
- 1-day range
- $7.23$7.71
- Market cap
- $487.98M
- P/E (trailing)
- —
- P/E (forward)
- 25.88
- EPS (trailing)
- $-0.53
- Dividend yield
- —
- Beta
- 1.36
- Avg. volume
- 892.3K
How Evolus Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 3, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Evolus Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- EOLSEvolus Inc. Common Stock$7.1▼ 6.21%Market cap $487.98MP/E —$3.86$9.31
- AQSTAquestive Therapeutics Inc. Common Stock$3.78▼ 6.90%Market cap $491.83MP/E —$2.93$7.55
- QTTBQ32 Bio Inc. Common Stock$7.52▼ 3.22%Market cap $482.18MP/E 7.95$1.91$23.57
- EVMNEvommune Inc. Common Stock$5.17▼ 12.82%Market cap $481.93MP/E —$6.52$33.2
- OVIDOvid Therapeutics Inc. Common Stock$2.15▼ 4.87%Market cap $494.60MP/E —$1.18$3.11
- TENXTenax Therapeutics Inc. Common Stock$1.36▼ 9.93%Market cap $498.11MP/E —$1.31$19.4
- BIOABioAge Labs Inc. Common Stock$4.84▼ 9.53%Market cap $500.98MP/E —$5.04$25.96
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EOLS Evolus Inc. Common Stock | $487.98M | — | $7.1 | ▼ 6.21% | $3.86$9.31 |
| AQST Aquestive Therapeutics Inc. Common Stock | $491.83M | — | $3.78 | ▼ 6.90% | $2.93$7.55 |
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 7.95 | $7.52 | ▼ 3.22% | $1.91$23.57 |
| EVMN Evommune Inc. Common Stock | $481.93M | — | $5.17 | ▼ 12.82% | $6.52$33.2 |
| OVID Ovid Therapeutics Inc. Common Stock | $494.60M | — | $2.15 | ▼ 4.87% | $1.18$3.11 |
| TENX Tenax Therapeutics Inc. Common Stock | $498.11M | — | $1.36 | ▼ 9.93% | $1.31$19.4 |
| BIOA BioAge Labs Inc. Common Stock | $500.98M | — | $4.84 | ▼ 9.53% | $5.04$25.96 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UTMD Trades at a Premium to the Industry: How to Play the Stock?Yahoo · 10/8/2026
- Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drugbenzinga · 10/2/2026
- FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective ActionYahoo · 10/2/2026
- Evolus Warned Over Misbranding in Social Media Promo for Frown Lines DrugBenzinga · 10/2/2026
- FDA Release Letter Date Sept. 28: Sends Letter To Evolus, Terms Co.'s Claims About JEUVEAU As MisleadingBenzinga · 10/2/2026
- Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important CausesYahoo · 10/1/2026
- Evolus Inc (NASDAQ:EOLS) Passes Minervini Trend Template and High Growth Momentum ScreenChartMill · 10/1/2026
Insider Activity
Insider Actions →- MOATAZEDI DAVID · September 2, 2026 · Sale105.1K @ $9.04
Institutional Ownership
March 31, 2026
- Total shares held
- 45.58M
- Total value held
- $186.81M
- Institutional holders
- 143
- Unknown6.38M
- Unknown4.29M
- Unknown3.11M
- Unknown2.63M
- Unknown2.47M
- Unknown2.25M
- Unknown2.18M
- Unknown1.46M
- Unknown1.40M
- Unknown1.38M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Evolus (EOLS) Passes Momentum Screens
Evolus Inc. has recently met the criteria for the Minervini Trend Template and a high growth momentum screen. This suggests the stock is showing signs of upward price strength and volume activity. While the company trades well below its average analyst target price, these technical signals indicate a shift in trading patterns.
Evolus (EOLS) Passes Momentum Screens. Evolus Inc. has recently met the criteria for the Minervini Trend Template and a high growth momentum screen. This suggests the stock is showing signs of upward price strength and volume activity. While the company trades well below its average analyst target price, these technical signals indicate a shift in trading patterns.